Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | AZD1775: Aiding in the treatment of glioblastomas

Manmeet Singh Ahluwalia, MD, from the Cleveland Clinic, Cleveland, OH, talks to us about his team’s research on glioblastoma and AZD1775, a WEE1 inhibitor that acts to make tumour cells more susceptible to destruction by chemotherapy and radiation. Current clinical trials on the drug are focused on investigating the safe dose for the drug in combination with radiation therapy and temozolomide (NCT01849146) and Phase II trials are planned for evaluating the efficacy of the combination regimen in treating glioblastomas. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.